PLG and atherosclerosis: First, Lp(a) promotes atherosclerosis and thrombosis by facilitating atherosclerotic plaque formation through its cholesterol-rich LDL-like structure, while its Apo(a) component, which resembles plasminogen, competitively inhibits the fibrinolytic system, thereby enhancing thrombotic potential and increasing the risk of ACS recurrence (47–49).